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Chronic  myelocytic  leukemia  (CML)  is  associated  with  the  presence  of  a 
Philadelphia (Ph 1) chromosome in 95% of cases (1). This cytogenetic hallmark is 
molecularly characterized by the translocation of the c-abl oncogene from chro- 
mosome 9 into the breakpoint cluster region (bcr) of chromosome 22 (2-5), and 
the subsequent transcription of a  chimeric 8.5 kb bcr/c-abl  RNA species within 
leukemic cells (6-8), which represents mRNA  for an altered c-abl protein with 
associated tyrosine kinase activity (9). PhLnegative CML, however, constitute a 
heterogeneous group of prognostically distinct disorders (10). Recently (11), my 
coworkers and I identified a phi-negative CML patient with a c-abl/bcr rearrange- 
ment; however, other patients lack this recombination (3). Here I report on the 
first Phi-negative CML patient whose leukemic cells exhibit a rearrangement in 
the bcr gene without juxtaposition of c-abl sequences. 
Materials and Methods 
Patients.  Patient  1  is  a  62-yr-old male  in  the  chronic phase  of Phi-positive CML. 
Patient 2  is a  48-yr-old male with splenomegaly; Hb,  107 g/liter; leukocytes, 95  ×  109 
cells/liter (52% neutrophils, 1% eosinophi]s, 3% basophiles, 9% myeloblasts, 24% myelo- 
cytes, 8% lymphocytes, 3% monocytes); 452 ×  109 platelets/liter; bone marrow revealed 
increased  myeloid  lines  without  major  maturation  disturbance;  repeated  cytogenetic 
analysis showed a male karyotype without chromosomal aberrations; this patient is being 
treated with hydroxyurea and has been in chronic state for 28 mo. 
DNA Analysis.  Bone marrow DNA (15 #g) obtained from both patients were digested 
with restriction enzymes (C.  F.  Boehringer & Soehne, Mannheim,  Federal Republic of 
Germany), electrophoresed on a 0.7% agarose gel, blotted, and hybridized to a 2 kb Bgl 
II/Hind III 5' bcr probe and a  1.2 kb Hind III/Bgl II 3' bcr probe as described (11).  h- 
DNA were included as molecular weight standards (not shown). Specific activity of the 
probes was  1-3.5  ×  108 cpm/#g.  After hybridization, filters were washed under high 
stringency (10% saline citrate, 65°C) and exposed to XAR-2 film (Eastman Kodak Co., 
Rochester, NY) for up to 3 d at -70°C with DuPont Lightening Plus intensifying screens 
(DuPont Instruments, Wilmington, DE). 
RNA Analysis.  RNA was isolated from bone marrow cells according to the LiCI/urea 
method (12);  poly(A) RNA was obtained after two passages  over oligo(dT) cellulose; 15 
#g  of poly(A)  RNA  was  electrophoresed on  a  1.2%  agarose  gel  in  the  presence  of 
formaldehyde (13).  After blotting, nitrocellulose filters (Schleicher and Schuell, Dassel, 
FRG)  were  first  hybridized  to  a  0.6  kb  Eco  RI/Bam  HI  c-abl  probe  washed,  and 
rehybridized to a 2 kb Bgl II/Hind III 5' bcr probe, as described (11). Filters were exposed 
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to Kodak XAR-5 film using DuPont Lightning Plus intensifying screens for up to 6 d at 
-70°C. 
In  Situ  Hybridization.  Chromosomes  obtained  from  bone  marrow  were  prepared 
according to standard techniques. After RNase treatment, chromosomes were denatured 
in 70% formamide/2× standard saline citrate (SSC) at 70°C for 2 rain, rinsed in 2x SSC, 
and dehydrated. The probe, a  1:1 mixture of human :3'  1.1  kb Hind III/Eco RI and 5' 
0.6 kb Bam HI c-abl  plasmids (3),  was labeled by nick-translation using [~H]dCTP and 
[3H]dTTP (New England Nuclear, Boston, MA) to a specific activity of 0.8 x  107 cpm/#g. 
The probe was denatured for 5  min at  70°C at a  concentration of 0.2 #g/ml in  50% 
formamide/2X SSC/10% dextran sulfate added to the chromosomes, and hybridized for 
10 h at 37°C; slides  were rinsed in three changes of 50% formamide/2× SSC at 39°C, 
followed by 6  h  washing  in  2:<  SSC  at  room temperature,  exposed to  Kodak NTB2 
emulsion, for 15 d at 4 ° C, developed, and stained with quinacrine mustard as described 
(11). 
Results 
Southern  blot analysis  revealed a  rearrangement  within  the  bcr  gene in  leu- 
kemic cells of a  phi-negative  CML  patient.  Hybridization to  5'  bcr  sequences 
detects a  5  kb germline band together with a  3.4 kb rearranged fragment (Fig. 
1,  lane 2). A  Bgl II polymorphism appears to be an unlikely explanation of this 
result,  since digests  using different restriction  enzymes (Barn  HI, Eco  RI, and 
Hind III) demonstrated a  similar pattern (not shown).  Hybridization to a  1.2 kb 
Hind III/Bgl II 3' bcr probe also identified an additional autoradiographic band. 
These results  are  comparable  to  the  data  obtained  in  phi-positive  CML  (e.g., 
Fig.  1, lane 1). 
To  investigate  a  possible  involvement  of  c-abl  sequences  in  this  genomic 
alteration,  I  performed in situ hybridization studies of c-abl sequences to meta- 
phase chromosomes of the phi-negative CML patient (Table I).  Distribution of 
silver grains obtained from analysis of 42 metaphases was uniform and at random 
on  all  chromosomes  except the  specific signal  (P  <  0.01)  on  chromosome  9. 
Analysis  by  Poisson  distribution,  with  the  number  of grains  per  chromosome 
adjusted for the relative size of the band in a  400-band idiogram (15), revealed 
highly significant (P << 10  -7) grain accumulation at band 9q34. Thus, in contrast 
to all  phi-positive CML patients  investigated so far (2-4),  in  situ  hybridization 
studies failed to detect a  translocation of c-abl sequences in leukemic cells of this 
patient. 
To elucidate in some more detail the consequences of these results I performed 
FIGURE  1.  Southern blot analysis  of bcr sequences of human placenta DNA (lane 0) and bone 
marrow DNA from two leukemic patients (lanes 1 and 2). DNA (15 #g) were digested with 
Bgl II, electrophoresed on a 0.7% agarose gel, blotted, and hybridized to a Bgl lI/Hind III 5' 
bcr probe that detects a 5 kb normal bcr fragment. BARTRAM  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Results of In Situ Hybridization  to Human c-abl Probes 
Chromosome  Grains observed  Grains expected 
1  9  17.5 
2  20  17.0 
3  9  14.1 
4  7  13.5 
5  15  12.9 
6  3  12.2 
7  14  11.2 
8  8  10.3 
9  42*  9.6 
1---0  ---t]---  9 .""~ 
11  6  9.6 
12  10  9,5 
13  6  7,5 
14  8  7,3 
15  9  6.8 
16  3  6,3 
17  5  6.0 
18  7  5.7 
19  1  4.4 
20  2  4.8 
21  5  3.3 
22  1  3.5 
X  3  10.9 
Y  2  3.7 
Number of grains expected  according to DNA content (14).  Analysis by Poisson 
distribution demonstrate a highly significant grain accumulation at band 9q34. 31 
grains on region 9q34. 
* 31 grains on region 9q34. 
2177 
FIC.UR~  2.  Northern  blot analysis of poly(A) RNA obtained  from patients  1 and 2. The  blot 
was first  hybridized  to  a  c-abl  probe  (A),  washed,  and  rehybridized  to  5'  bcr sequences  (B). 
Arrow  points  to a  novel  7.3  kb  bcr  RNA  species  in  leukemic  cells  of patient  2.  Molecular 
weight standards are not shown. 
an RNA analysis. Northern blots hybridized to c-abl sequences showed 6 and 7 
kb normal abl RNA species, as well as the fused 8.5 kb transcript in Phi-positive 
CML  (Fig.  2A,  lane  1);  in  the  Phi-negative  CML  patient,  only normal  c-abl 
species were visible  (Fig.  2A,  lane 2).  Rehybridization  of the  filters to  5'  bcr 
sequences,  however,  led  to  the  detection  of a  novel  7.3  kb  bcr  transcript  in 
leukemic cells of this individual (Fig.  2B,  lane 2) replacing a  6.7  kb normal bcr 
transcript  (8);  the  8.5  kb  chimeric  RNA  species  (7,  8)  demonstrated in  Ph 1- 
positive CML (Fig. 2B, lane 1). 2178  BARTRAM  BRIEF  DEFINITIVE REPORT 
Discussion 
Molecular analysis of the Ph 1 translocation in CML led to the identification of 
the  bcr  gene  on  chromosome  22.  A  modification of the  c-abl  protein  by N- 
terminal  substitution  of bcr  sequences  appears  to  be  a  crucial  event  in  the 
development of Phi-positive CML. Chronic myelocytic leukemia without a Ph ~ 
chromosome comprises a heterogenous group of related disorders. Recent evi- 
dence (3,  11) suggests that a  subset of cytogenetic Phi-negative CML patients 
may in fact belong to the molecularly defined entity of Phi-positive CML, while 
leukemic cells of other Phi-negative CML patients lack a c-abl/bcr rearrangement. 
Here  I  report  on  yet  another  type  of genomic  recombination,  i.e.,  a  bcr 
rearrangement without involvement of c-abl sequences.  Data obtained by both 
in situ hybridization studies and Northern blotting demonstrate that this onco- 
gene is neither translocated nor abnormally transcribed in the Phi-negative CML 
patient described here. However, a rearrangement within bcr leads to a replace- 
ment of normal 4.5 and 6.7 kb bcr RNA species (7) by a novel 7.3 kb transcript 
in leukemic cells of this individual. 
Chronic myelocytic leukemia is a  clonal disease of pluripotent hematopoietic 
stem  cells,  and  the  expression  of bcr  may be  closely associated with  this  cell 
lineage.  However, the normal function of the bcr-encoded  product is still  un- 
known. The detection of a rearrangement within bcr per se is in all likelihood 
not a sufficient explanation for the development of myeloid leukemia. As for the 
patient described herein, it may be possible that bcr sequences are  fused with 
other, yet unknown sequences, instead of c-abl.  Molecular cloning and detailed 
analysis of the novel bcr transcript may substantiate this speculation. However, 
the demonstration of heterogeneity among phi-negative CML cases detected by 
bcr and c-abl sequences may finally contribute to a novel subclassification of this 
poorly  defined  group  of leukemias  based  on  molecular,  morphological,  and 
clinical features. 
Summary 
Southern blot analysis detected a bcr gene rearrangement within leukemic cells 
of a  Philadelphia  chromosome-negative chronic  myelocytic leukemia  (CML) 
patient that led to transcription of a novel 7.3 kb bcr RNA species.  Participation 
of the c-abl oncogene in this genomic recombination could be ruled out by in 
situ hybridization studies and Northern blot analysis. 
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